Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab

Autor: Corominas, Héctor, Alegre, Cayetano, Narváez García, Francisco Javier, Fernández-Cid, Carlos Marras, Torrente Segarra, Vicenç, Gómez Rodríguez, Manuel, Maceiras Pan, Francisco, Morlà, Rosa, Martínez Rodríguez, Fernando José, Gómez-Centeno, Antoni, Losada Ares, Laura, Gonzalez Molina, Rocío, Paredes González-Albo, Silvia, Dalmau-Carolà, Joan, Pérez-García, Carolina, Barbazán Álvarez, Ceferino, Ercole, Liliana, Terrancle, Maria Ángeles, ACT-AXIS Study Group.
Přispěvatelé: Institut Català de la Salut, [Corominas H] Departament de Reumatologia, Hospital Sant Joan Despí Moises Broggi, Sant Joan Despí, Spain. [Alegre C] Servei de Reumatologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Narváez J] Departament de Reumatologia, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain. [Fernández-Cid CM] Department of Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain. [Torrente-Segarra V] Departament de Reumatologia, Hospital General de l'Hospitalet, L'Hospitalet de Llobregat, Spain. [Gómez MR] Department of Rheumatology, Complejo Hospitalario Cristal Piñor, Ourense, Spain., Vall d'Hebron Barcelona Hospital Campus
Rok vydání: 2019
Předmět:
rheumatoid arthritis
Male
Pathological Conditions
Signs and Symptoms::Signs and Symptoms::Fatigue [DISEASES]
Arthritis
Disease
Musculoskeletal Diseases::Musculoskeletal Diseases::Rheumatic Diseases::Arthritis
Rheumatoid [DISEASES]
Arthritis
Rheumatoid
chemistry.chemical_compound
0302 clinical medicine
Amino Acids
Peptides
and Proteins::Proteins::Blood Proteins::Amino Acids
Peptides
and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Antibodies
Monoclonal::Amino Acids
Peptides
and Proteins::Proteins::Antibodies
Monoclonal
Humanized [CHEMICALS AND DRUGS]
Medicine
aminoácidos
péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados [COMPUESTOS QUÍMICOS Y DROGAS]
Prospective Studies
Other subheadings::/therapeutic use [Other subheadings]
030212 general & internal medicine
skin and connective tissue diseases
Prospective cohort study
Otros calificadores::/terapia [Otros calificadores]
Fatigue
Depression (differential diagnoses)
Depression
General Medicine
Middle Aged
clinical practice
C-Reactive Protein
Treatment Outcome
patient-reported outcomes
Antirheumatic Agents
030220 oncology & carcinogenesis
Rheumatoid arthritis
Retreatment
Female
Psychosocial
Research Article
musculoskeletal diseases
Farmacologia
medicine.medical_specialty
Artritis reumatoide - Tractament
Observational Study
Artritis reumatoide
Antibodies
Monoclonal
Humanized
tocilizumab
03 medical and health sciences
Tocilizumab
Internal medicine
Humans
afecciones patológicas
signos y síntomas::signos y síntomas::fatiga [ENFERMEDADES]
enfermedades musculoesqueléticas::enfermedades musculoesqueléticas::enfermedades reumáticas::artritis reumatoide [ENFERMEDADES]
Pharmacology
Tumor Necrosis Factor-alpha
Otros calificadores::/uso terapéutico [Otros calificadores]
Fatiga
business.industry
Other subheadings::/therapy [Other subheadings]
medicine.disease
chemistry
fatigue
Observational study
Sleep
business
Anticossos monoclonals
Biomarkers
Zdroj: Dipòsit Digital de la UB
Universidad de Barcelona
Scientia
Medicine
ISSN: 1536-5964
0025-7974
DOI: 10.1097/md.0000000000015947
Popis: Rheumatoid arthritis; Fatigue; Tocilizumab Artritis reumatoide; Fatiga; Tocilizumab Artritis reumatoide; Fatiga; Tocilizumab To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ.A 24-week, multicenter, prospective, observational study in patients with moderate to severe RA receiving TCZ after failure or intolerance to disease-modifying antirheumatic drugs or tumor necrosis factor-alpha was conducted.Of the 122 patients included, 85 were evaluable for effectiveness (85% female, 51.9 ± 12.5 years, disease duration 8.7 ± 7.4 years). Mean change in C-reactive protein level from baseline to week 12 was -11.2 ± 4.0 (P
Databáze: OpenAIRE
Externí odkaz: